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Background: It is known that there is significant morbidity associated with urinary tract infection
and with renal dysfunction in sickle cell disease (SCD). However, it is not known if there are
potential adverse outcomes associated with asymptomatic bacteriuria (ASB) infections in sickle cell
disease if left untreated. This study was undertaken to determine the prevalence of ASB, in a cohort
of patients with SCD.
Methods: This is a cross-sectional study of patients in the Jamaican Sickle Cell Cohort. Aseptically
collected mid-stream urine (MSU) samples were obtained from 266 patients for urinalysis, culture
and sensitivity analysis. Proteinuria was measured by urine dipsticks. Individuals with abnormal
urine culture results had repeat urine culture. Serum creatinine was measured and steady state
haematology and uric acid concentrations were obtained from clinical records. This was completed
at a primary care health clinic dedicated to sickle cell diseases in Kingston, Jamaica. There were 133
males and 133 females in the sample studied. The mean age (mean ± sd) of participants was 26.6 ±
2.5 years. The main outcome measures were the culture of ≥ 105 colony forming units of a urinary
tract pathogen per milliliter of urine from a MSU specimen on a single occasion (probable ASB) or
on consecutive occasions (confirmed ASB).
Results: Of the 266 urines collected, 234 were sterile and 29 had significant bacteriuria yielding a
prevalence of probable ASB of 10.9% (29/266). Fourteen patients had confirmed ASB (prevalence
5.3%) of which 13 had pyuria. Controlling for genotype, females were 14.7 times more likely to
have confirmed ASB compared to males (95%CI 1.8 to 121.0). The number of recorded visits for
symptomatic UTI was increased by a factor of 2.5 (95% CI 1.4 to 4.5, p < 0.005) but serum
creatinine, uric acid and haematology values were not different in patients with confirmed ASB
compared with those with sterile urine. There was no association with history of gram negative
sepsis.
Conclusion: ASB is a significant problem in individuals with SCD and may be the source of
pathogens in UTI. However, further research is needed to determine the clinical significance of ASB
in SCD.
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Background
The definition of asymptomatic bacteriuria (ASB) is con-
troversial as some have defined it as the quantitative
growth of bacteria, greater than or equal to 105 colony
forming units per milliliter urine of the same organism,
on aseptically collected midstream urine specimens, in
the absence of symptoms of urinary tract infection on two
or more consecutive occasions [1,2] while for others a sin-
gle occasion is sufficient [3-5]. The prognostic significance
of ASB resides in the observation that persons with ASB in
certain medical conditions, such as diabetes mellitus and
pregnancy, are at increased risk of pyelonephritis and
renal impairment [5-7].
In sickle cell disease renal disease and dysfunction are
common and increase morbidity and mortality [8,9].
Additionally, symptomatic urinary tract infection (UTI) is
associated with painful crisis, bacteraemia, pneumonia,
and osteomyelitis in SCD [10-13]. Whether ASB is a prel-
ude to more serious renal disease and dysfunction in SCD
is unclear. This present study was undertaken to estimate
the prevalence and possible risk factors of ASB in the
Jamaican sickle cell cohort.
Methods
Patients
The sample comprised a group of patients in the Jamaican
Sickle Cell Cohort attending the 2004 Annual Sickle Cell
Cohort Review conducted at the Sickle Cell Unit Clinic at
the University of the West Indies, Kingston, Jamaica. The
Jamaican Sickle Cell Cohort includes patients with sickle
cell diseases detected using standard criteria during
screening of 100,000 consecutive non-operative deliveries
at a large maternity hospital (the Victoria Jubilee Hospi-
tal) between 1973 and 1981. This screening yielded 580
patients with different sickle genotypes, of which 315 had
HbSS disease, 201 Sickle cell-haemoglobin C, 33 Sickle
cell-β+ thalassaemia, 14 Sickle cell-β0 thalassaemia and 17
sickle variants. They have been followed clinically since
birth [14]. At the 2004 cohort review 267 of 302 patients
eligible to attend the annual cohort review were seen. The
reasons for being absent were: Twenty-two of the patients
did not attend the review that year, 11 were lost to follow
up, or incarcerated, and 2 were ill at the time of review.
One patient refused to leave a sterile urine sample during
the cohort review period, thus the final participating
patient sample for this study was 266 patients. Ethical
approval was granted for this study by the University Hos-
pital of the West Indies, University of the West Indies Fac-
ulty of Medical Sciences Ethics Committee.
Measurements
Aseptically collected midstream urines (MSUs) were
obtained from the symptom free attendees of 2004 cohort
review and sent on the same day for microbiological cul-
ture. Urinalysis was performed on aliquots of the MSU
specimen using the QuickVue UrinChek™10+SG test
strips. Bacterial culture was performed by streaking 0.002
mL of midstream collected urine with a calibrated loop on
MacConkey and 5% sheep blood agar plates. These agar
plates were incubated at 35°C for 24 hours under aerobic
conditions. Isolates were considered significant if there
were ≥ 105 colony forming unit/mL (CFU/mL) with 2 or
less isolates, doubtful significance if 104 – 105 CFU/mL,
insignificant if < 104 CFU/mL. Mixed growths, in any
count, of more than two organisms were considered to be
contaminated. Significant isolates were selected for iden-
tification and antimicrobial susceptibility testing using
the vitek (biome'rieux' version R06.01, Missouri USA).
Proteinuria was defined as a protein reading of trace or
greater on dipstick urinalysis.
Patients complaining of any symptoms, whether related
or unrelated to the urinary tract, were not included in the
study on that day. Rather, these patients were treated for
their complaint and studied on another day when they
were without symptoms. Subjects whose urine microbio-
logical report was abnormal were asked to return to the
unit for a repeat midstream urine collection and culture.
Blood samples were also taken for the measurement of
serum creatinine. Serum creatinine were measured in the
Tropical Medicine Research Institute laboratory with an
Abbott ALCYON 300I, using the alkaline picrate method.
The clinical records of all cohort patients in the sickle cell
unit database were examined and the following informa-
tion extracted: age, gender, steady state haematology,
steady state uric acid levels, history of urinary tract infec-
tion, and history of gram negative sepsis.
Definition of asymptomatic bacteriuria
Probable ASB was defined as the presence of at least 105
colony forming units of a urinary tract pathogen per mil-
liliter of urine in a culture of a midstream urine specimen
obtained from a patient during the cohort review visit. A
confirmed episode of asymptomatic bacteriuria was
defined as two or more consecutive cultures with evidence
of asymptomatic bacteriuria due to the same urinary tract
pathogen with the same sensitivity pattern. A sample was
deemed grossly contaminated if it grew more than two
urinary tract pathogens even if in significant quantities.
Statistical methods
Values are expressed as counts or means ± sd as appropri-
ate. The prevalence of probable ASB and confirmed ASB
were determined as the ratio of the number of urines clas-
sified as probable ASB and confirmed ASB, to the total
number of collected MSU samples. The 95 percent confi-
dence interval (95%CI) for this proportion was computedBMC Infectious Diseases 2006, 6:46 http://www.biomedcentral.com/1471-2334/6/46
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according to the Wilson score method without continuity
correction [15]. For continuous outcome variables differ-
ences in means between ASB status (confirmed ASB group
vs. sterile urine group) and genotype were determined by
two factor analysis of variance. Associations between cat-
egorical exposures and ASB status were adjusted for geno-
type by Mantel-Haenszel methods. Logistic regression was
used to examine the relationship between potential pre-
dictors (age, history of urinary tract infection, genotype,
steady state haematology, uric acid and serum creatinine)
and probability of having ASB. Likelihood ratio tests were
used to determine which predictors would be included in
the final model. We assessed differences in the frequency
of past attendance for symptomatic urinary tract infection
between ASB status and genotype using a negative bino-
mial regression model. Clinic visits less than 14 days apart
were considered the same event. Visits were assumed to be
independent between individuals but repeat visits by indi-
viduals were not assumed to be independent. Data were
analyzed using the Stata statistical software version 8
(Statacorp, TX, USA). Tests were considered significant if
p < 0.05.
Results
A total of 267 patients attended the 2004 cohort review.
One person refused to participate in the study. Thus 266
patients had screening clean-catch MSU (Figure 1), of
which 50% were male. One woman was pregnant at the
cohort review visit; and another became pregnant during
follow-up of the first abnormal MSU.
As expected there were significant differences in the hae-
matological values by genotype with the mean steady
state haemoglobin levels of HbSS group being signifi-
cantly lower than sickle cell-haemoglobin C group, sickle
cell-β+ thalassaemia, and sickle variants but having higher
steady state nucleated cell counts (Table 1). The steady
state serum creatinine values were significantly lower in
the HbSS group compared with other genotypes except
the sickle variant group. In addition the mean uric acid
values were lower in the HbSS group compared with sickle
cell-β+ thalassaemia group (Table 1).
There were 32 patients with abnormal first MSUs: 29 were
positive MSU samples growing identifiable pathogens
(Figure 1), 2 were grossly contaminated and one grew bac-
teria of doubtful significance (growth of a urinary tract
pathogen between 104 and 105 per mL). Of the 29 positive
cultures 15 re-grew the same organisms in the next culture
but one of these grew the same organism (E. coli) but with
a different sensitivity pattern and was therefore classified
as a probable ASB. Thus 14 samples satisfied the criteria
for a confirmed episode of asymptomatic bacteriuria (Fig-
ure 1) yielding a prevalence of 5.3% (95% CI 0.8% to
29.4%). Fifteen subjects were classified as probable ASB.
The probable ASB group consisted of seven samples which
grew organisms that were different from the first MSU
sample, 2 grew bacteria in insignificant quantities, four
were no growth and two were grossly contaminated spec-
imens (Figure 1). None of the patients were on antibiotic
therapy during this study and all of the patients with iden-
tified ASB had at least one follow-up visit.
Sixteen of the 29 positive first MSU samples (55%) grew
E. coli in significant quantity. This was the commonest
organism cultured in this study. Other urinary tract path-
ogens identified in this study included: group B Streptococ-
cus,  Enterobacter aerogenes, coagulase negative
Staphylococcus, Enterobacter cloacae, Proteus mirabilis, Micro-
aerophilic streptococcus and Bacteroides  (mixed), group B
Streptococcus  and  Streptococcus viridans (mixed),  Entero-
bacter species, group D Streptococcus, Klebsiella pneumoniae,
and Enterobacter koseri. All of these organisms were grown
in pure cultures with only the two exceptions listed above.
Fifteen of the patients with probable ASB (52%) had evi-
dence of a host response, as evidenced by pyuria. Of those
with confirmed ASB, 13 of 14 patients (93%) had a host
response as evidenced by pyuria in the second midstream
urinalysis.
There were no significant differences for mean haemo-
globin and nucleated blood cell counts between the con-
Number of urine samples by microbiological classification Figure 1
Number of urine samples by microbiological classification.
All MSU
266
Abnormal Abnormal
N=32 N=32
Normal Normal
N=234 N=234
ASB ASB
N= N=29
Doubtful Doubtful
N=3
Confirmed ASB Confirmed ASB
14 (5.3%)
Probable ASB Probable ASB
15 (5.3%)
Indeterminate Indeterminate
N=3
Significant growth of 
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firmed ASB group and sterile urine group (86.4 ± 15.2 g/L
vs. 92.6 ± 17.4 g/L and 14.0 ± 4.5 × 109/L vs. 13.4 ± 4.1 ×
109/L) respectively. Similarly there were no differences in
mean serum creatinine and uric acid values between the
confirmed ASB group and sterile urine group (Table 2).
Twelve and a half percent (1/8) of patients with ASB had
proteinuria of trace or greater on dipstick urinalysis. How-
ever there was no association between having proteinuria
measured by dipstick and ASB (Table 2).
The proportion of subjects with HbSS in the confirmed
ASB group (64%) was not statistically different from the
proportion of HbSS in the sterile group (55%). However
controlling for genotype, females were 14.7 times more
likely to have confirmed ASB compared to males (95%CI
1.8 to 121.0) but having a recorded history of ever having
a symptomatic UTI was not associated with current ASB
status (Odds ratio 2.5, 95%CI 0.79 to 7.76). The numbers
of recorded episodes of gram negative sepsis were few.
Notwithstanding, there were 148 clinic visits for sympto-
matic urinary tract infections (Table 2). Compared to the
sterile urine group the expected number of visits for symp-
tomatic UTI in the confirmed ASB group is increased by a
factor of 2.5 (95% CI 1.4 to 4.5, p < 0.005).
The relationship between the various predictors and prob-
ability of having ASB were explored with a series of logistic
regression models. Likelihood ratio tests were used to
determine which variables should be incorporated into a
final regression model with ASB as the response variable.
The results indicated that the absence of the variables
HbSS genotype (coded as 1 for homozygous βs, 0 other-
wise), steady state haematology, and serum creatinine
from the full model which included these variables along
with age, gender (coded as 1 for female, 0 otherwise) and
steady state uric acid concentrations as predictors did not
significantly reduce the log likelihood. Thus the model
which best predicted ASB from the data included the pre-
dictors age OR 1.37 (95 % CI: 0.99 1.64), female gender
OR 15.3 (95% CI: 1.94, 120.1), and uric acid concentra-
tion OR 21.5 (95% CI: 0.64, 722.2) (Table 3).
Discussion
The prevalence of probable ASB was 10.9% and the prev-
alence of confirmed ASB was 5.3% with 95% CI 0.8% to
29.4% in this sample of Sickle Cell patients. These preva-
lence rates are comparable to other prevalence estimates
of ASB in non-sickle cell healthy populations [5,16]. The
major determinants of ASB status were gender, age and
steady state serum uric acid concentrations. Additionally
there were increased numbers of recorded clinical visits
for symptomatic UTI in the confirmed ASB group. The
effect of genotype status on these relationships was not
statistically significant.
The strength of this study is related to the cohort design
which resulted in the selection of a representative popula-
tion based sample. This reduces the ascertainment bias
associated with symptomatic recruitment from a clinic
based population. In addition, the participation rates at
this cohort review were >99%, thus strengthening our
confidence in extrapolating our findings to the wider
sickle cell population. However the small number of
patients identified with confirmed ASB represents a limi-
tation of the present study.  This was partly due to our con-
servative definition of confirmed ASB. The consequence
of having a small numerator is that the precision of our
prevalence estimate is affected and this is reflected in a
wide 95% confidence interval.
The sexual dimorphism in the prevalence of ASB has been
reported before in healthy adults [6]. It is thought that this
Table 1: Clinical Characteristics of enrolled subjects by genotype (N = 266).
Clinical characteristics HbSS N = 148 HbSC N = 85 HbSβ0 N = 6 HbSβ+ N = 22 Sickle variants* N = 5
Age yr 26.4 ± 2.6 27 ± 2.3 25.9 ± 2.3 26.5 ± 2.5 25.1 ± 2.5
†Gender (M:F) 71:77 38:47 2:4 13:9 4:1
#Creatinine µmol/L 45.7 ± 9.4a 63.3 ± 11.7b 70.7 ± 23.1b 61.9 ± 12.4b 62 ± 20.4a
#Uric Acid mmol/L 0.3 ± 0.1a 0.3 ± 0.1a 0.4 ± 0.1a 0.4 ± 0.3b 0.3 ± 0.1a
#Haemoglobin g/L 80.2 ± 9.9a 108.2 ± 8b 91.6 ± 11.8b 109.9 ± 12.4b 124 ± 22.1b
#Nucleated Blood cells × 109/Lc 15.9 ± 3.2a 10.2 ± 2.9b 13.3 ± 2.2b 9.2 ± 2.7b 9.9 ± 2.5b
†Proteinuria ≥ trace : No proteinuria (n = 182) 17 7 0 1 0
†Positive History of gram negative sepsis 2 2 0 0 0
†Positive recorded history of ever having UTI 50 25 2 1 1
Values are means ± sd ; † values are counts. Abbreviations – HbSS = Homozygous sickle cell disease, HbSC= Sickle cell-haemoglobin C, HbSβ0 = 
Sickle cell-β0 thalassemia, HbSβ+ = Sickle cell-β+ thalassemia; UTI= Urinary Tract Infections.
* Sickle variants include sickle cell-hereditary persistence of foetal haemoglobin, sickle cell -haemoglobin O Arab, sickle cell -haemoglobin Lepore-
Boston.
# Significant difference in mean values by genotype. Dissimilar superscript to HbSS values are significantly different (p < 0.03)BMC Infectious Diseases 2006, 6:46 http://www.biomedcentral.com/1471-2334/6/46
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may be related a relative deficiency of secretory IgA anti-
body response from the mucosal surface in the urogenital
tract of females compared with males [6].
In non pregnant females the presence of confirmed ASB
has a high sensitivity and specificity of predicting a future
symptomatic episode of UTI [5,6]. However in the
absence of anatomical or functional abnormalities of the
urinary tract, ASB per se is not associated with renal scar-
ring, renal dysfunction or hypertension [17]. In adults
with SCD, anatomical abnormalities such as renal cortical
scarring, enlarged glomeruli, vascular disorganization of
the medulla and renal functional abnormality such as
increased effective renal blood flow and hyperfiltration
are common [8]. These pathophysiological changes are
thought to contribute to sickle cell nephropathy and the
high prevalence of renal failure observed in subjects with
sickle cell disease [8]. In this context, one might expect
persons with ASB to have more UTI and worse renal func-
tion. Thus the finding of an increased number of expected
visits for symptomatic UTI in subjects with ASB compared
to those without as well a trend for a significant associa-
tion between ASB status and a history of UTI is not sur-
prising. On the other hand, the absence of significant
differences in measures of renal function between those
with ASB and those without ASB was unexpected. How-
ever, serum creatinine and uric acid are not sensitive
measures of renal function as glomerular filtration rate
has to fall by up to 50% before there are changes in serum
creatinine [18,19]. Additionally variation in creatinine
production due to differences in muscle mass may alter
serum creatinine levels independent of renal functional
status [20,21]. Notwithstanding, further prospective stud-
ies are needed to define the renal risk posed by ASB in
sickle cell disease and to inform therapeutic strategies.
In sickle cell disease, the increased purine turnover associ-
ated with accelerated erythropoesis results in the greater
production of uric acid [22]. This is counterbalanced by
increased renal clearance of urate. It is possible that the
increased renal clearance may play a predisposing role for
ASB by promoting the formation of microcrystals which
damage the uroepithelium thereby facilitating coloniza-
tion.
The infecting organisms identified in this study are in
keeping with commonly isolated bacteria in other studies
[1-3,5,10,11]. The presence of bacteria in the urine in the
absence of a major inflammatory response and hence
symptoms, suggest that there are alterations in the host-
pathogen interaction. For example it has been reported
that uropathogenic strains of microbes have evolved
mechanisms to promote survival in the urinary space. Fea-
tures of these adaptive mechanisms include presence of
adhesion which promote attachment to the urogenital
tract, and the production of factors such as α-haemolysin,
Table 2: Clinical characteristics of enrolled subjects with confirmed ASB and sterile urine (N = 248)*
Clinical characteristics Confirmed ASB N = 14 Sterile urine N = 234
Age yr 27.9 ± 2.3 26.4 ± 2.5
†Gender (M:F) 1:13 124:110
#Genotype frequency (HbSS:HbSC:HbSβ0:HbSβ+: sickle variants) 9:2:1:2:0 130:75:5:19:5
Creatinine µmol/L 49.1 ± 12.4 53.7 ± 14.3
Uric Acid mmol/L 0.36 ± 0.29 0.33 ± 0.08
†Proteinuria ≥ trace : No proteinuria (n = 168) 1:7 22 :138
†Positive History of gram negative sepsis 1 1
†Positive recorded history of ever having UTI 7 25
†Cumulative number of recorded clinic visits for symptomatic UTI* 18 49
*Values of subjects with probable ASB excluded from table. † Values are counts. Abbreviations : ASB = asymptomatic bacteriuria; HbSC= Sickle cell-
haemoglobin C, HbSβ0 = Sickle cell-β0 thalassemia, HbSβ+ = Sickle cell-β+ thalassemia; UTI = Urinary Tract Infections
#Sickle variants include sickle cell-hereditary persistence of foetal haemoglobin, sickle cell -haemoglobin O Arab, sickle cell -haemoglobin Lepore-
Boston;
Table 3: Model predicting asymptomatic bacteriuria in the Jamaica Sickle Cell Cohort.
Variables Odds ratio P value Lower 95% CI Upper 95% CI
Age years 1.37 0.057 0.99 1.64
Female (coded as 1) 15.3 0.010 1.94 120.12
Uric acid mmol/l 21.5 0.087 0.64 722.21BMC Infectious Diseases 2006, 6:46 http://www.biomedcentral.com/1471-2334/6/46
Page 6 of 6
(page number not for citation purposes)
and cytotoxic necrotizing factor 1 (CNF1) [6]. On the
other hand the host factors in SCD that increases suscep-
tibility to bacterial colonization are unclear but in Diabe-
tes Mellitus altered leukocyte function contribute to the
susceptibility to ASB in this disease [23].
Conclusion
In summary ASB is a significant problem in individuals
with SCD and is associated with UTI. However, further
research is needed to determine the clinical and renal sig-
nificance of ASB in SCD.
Abbreviations
SCD: sickle cell disease, ASB: asymptomatic bacteriuria,
MSU: midstream urine, UTI: urinary tract infection, CFU:
colony forming unit.
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